Neurocrine Biosciences (NBIX) Revenue (2010 - 2026)

Neurocrine Biosciences has reported Revenue for 16 years, with the latest figure at $814.5 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 42.25% year-over-year to $814.5 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 billion (up 28.59% YoY), and the FY2025 full-year result was $2.9 billion, up 21.45% from the prior year.
• Revenue for Q1 2026 stood at $814.5 million, up from $805.5 million in the prior quarter.
• The five-year high for Revenue was $814.5 million in Q1 2026, with the low at $20.0 million in Q2 2022.
• Historically, Revenue has averaged $532.2 million across 5 years, with a median of $515.3 million in 2024.
• Annual changes were most pronounced in 2022 — Revenue sank 93.08% — and 2023, when it jumped 2163.5%.
• Neurocrine Biosciences' Revenue stood at $412.0 million in 2022, then advanced by 25.05% to $515.2 million in 2023, then advanced by 21.84% to $627.7 million in 2024, then climbed by 28.33% to $805.5 million in 2025, then advanced by 1.12% to $814.5 million in 2026.
• The last three Revenue figures came in at $814.5 million (Q1 2026), $805.5 million (Q4 2025), and $794.9 million (Q3 2025), per Business Quant data.